BioWorld

Aug. 28, 2008

Direct Reprogramming Is New Cell Source for Regeneration

NexMed Shares Fall Hard as Novartis Nixes NDA

Other News To Note

Clinic Roundup

Cell Genesys Falls 70% as Patient Deaths Derail GVAX Phase III

In yet another setback for cancer vaccines, Cell Genesys Inc. terminated one of its two Phase III trials with prostate cancer vaccine GVAX. (BioWorld Today) Read More

Amylin Sinks on Further Byetta Worries: More Deaths Reported

Today's news in brief

BioWorld

BioWorld briefs for June 5, 2026.

New York University identifies new analogues of mannose-6-phosphate

BioWorld Science

New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...

Bial-Portela discovers new OX1 receptor antagonists

BioWorld Science

Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...

FB-7033 demonstrates efficacy in MASH management

BioWorld Science

17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...

Illustration of antibody carrying radioactive isotope

Preclinical results support Actinium’s radioconjugate ATNM‑400 for NSCLC

BioWorld Science

At the recent meeting of the Society of Nuclear Medicine and Molecular Imaging, researchers from Actinium Pharmaceuticals Inc. presented preclinical efficacy data...